Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0600

+16.5%

3:10 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	7/20/2012 8:36:58 AM
	of 13111

LIver cancer FDA phase 3 trial failure Bristol-Myers Squibb Says Brivanib Fails Primary Goal In Trial. The Wall Street Journal (7/20, Rubin, Subscription Publication) reports that Bristol-Myers Squibb Co. announced yesterday that brivanib failed to meet its primary goal in a Phase 3 trial of matching sorafenib (Nexavar) for increasing survival of patients with advanced hepatocellular carcinoma. Reuters (7/20, Pierson) also reported the news.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next